Tradipitant: A Novel NK-1 Receptor Antagonist for the Management of Motion Sickness- A New Era in Drug Development

Abstract

Motion sickness affects millions of individuals worldwide and is characterized by symptoms such as nausea and vomiting. Historically, its management has primarily relied on anticholinergic and antihistamine agents, with limited therapeutic innovation over the past four decades. Tradipitant, a novel neurokinin-1 (NK-1) receptor antagonist, represents a significant advancement in treatment and has recently received FDA approval for motion sickness–related symptoms. It exerts its effect by blocking substance P, a key neurotransmitter in the emetic pathway. Tradipitant demonstrates high affinity for NK-1 receptors, while its metabolites (M2, M3, M4, and M8) exhibit comparable activity. From a pharmacokinetic perspective, it shows delayed absorption with food, a large volume of distribution (1,956 L), high plasma protein binding (~96%), and an elimination half-life of approximately 34 hours. It is primarily metabolized via cytochrome P450 pathways and is predominantly excreted in feces. Phase 3 clinical trials (Motion Syros and Motion Serifos) confirmed its efficacy in reducing the incidence of vomiting compared with placebo. Tradipitant was generally well tolerated and represents a promising new therapeutic option for the management of motion sickness.